# Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes

> **NIH NIH K23** · EMORY UNIVERSITY · 2020 · $191,737

## Abstract

Project Summary/Abstract
Diabetes affects up to 40% of patients with end-stage renal disease (ESRD). Diabetes
management in the context of existing ESRD is challenging due to alterations on glucose
metabolism, insulin sensitivity, and also renal clearance of several medications. Thus, most
patients with diabetes on dialysis are treated with insulin therapy, resulting in increased risk for
hospitalizations for hypoglycemia, mortality, length-of-stay and hospitalization costs at a national
level. In many instances, clinicians and patients need to make treatment decisions based on few
point-of-care blood glucoses (POC BG) per day, which fails to detect asymptomatic and
nocturnal hypoglycemia and are not a good indicator of the 24-hours glycemic excursions.
Novel factory-calibrated continuous glucose monitoring (CGM) devices have shown improved
accuracy and could fill the critical need for better glycemic monitoring systems in dialysis
patients. In this proposal, the PI, Dr. Galindo, will use CGM (Aim 1a) to examine the prevalence
of hypoglycemia, hyperglycemia and estimate glycemic variability patterns among patients with
type 2 diabetes (DM2), treated with insulin and receiving hemodialysis, (Aim 1b) to assess the
accuracy of the CGM in this specific cohort, (Aim 2a) to assess the efficacy of real-time CGM
data in preventing hypoglycemia and hyperglycemia, and (Aim 2b) to examine the relationship
between glycemic variability and inflammatory/oxidative stress markers in patients participating
in Aim 2a. We anticipate that this study will provide novel insights into the glycemic exposure
patterns among dialysis patients and will provide preliminary data for future outcomes-based
studies determining the best glycemic targets for this group. Dr. Galindo has created a
multidisciplinary mentorship team with track record of NIH funding, led by Dr. Umpierrez, with
expertise in glucose monitoring and research methodology, and Dr. Tuttle, who is an expert on
clinical and translational studies in diabetic kidney disease. His scientific advisory committee
includes experts in biostatistics and bioinformatics (Dr. Limin Peng, PhD), and in CGM
technology for (Dr. Beck). Dr. Galindo will test the proposed aims within the vast resources
available at Emory University - a world-known research institution. The career development plan
includes didactic classes, mentored-based training on clinical research and hands-on
experience on CGM use and large database analyses. This innovative proposal and formal
training plan, will provide Dr. Galindo with the bases for future R01 applications, and an
independent career in patient-oriented clinical research.

## Key facts

- **NIH application ID:** 9871850
- **Project number:** 1K23DK123384-01
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Rodolfo Galindo
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $191,737
- **Award type:** 1
- **Project period:** 2020-02-15 → 2024-12-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9871850

## Citation

> US National Institutes of Health, RePORTER application 9871850, Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes (1K23DK123384-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9871850. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*